Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:11/7/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 LayerBio, Inc., an MIT spinoff ... first round of seed financing from friends and family ... to develop a novel sustained-release product for ophthalmology. , ... and their commitment to this important work," said Dr. ... one of many areas in which innovations in drug ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and ... in China and the United,States, today announced that ... Vice,President of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Yu worked at Pfizer Inc., where,she co-led Pfizer,s ...
... Archi-Tech Systems, a,leading provider of pharmaceutical ... PromoTrack, a new solution custom-designed to,rapidly measure ... promotions. Archi-Tech has tailored its proven DART ... marketers, seamlessly,integrating disparate promotional campaign and Rx ...
... Inc.,(TSX: SDI) today announced that it has entered ... Medical for Spectral,s Endotoxin,Activity Assay (EAA(TM)), the only ... the terms of the agreement, BB Medical will ... "BB Medical is a leading distributor of medical ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 2Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay 2
(Date:7/29/2014)... parents of preterm babies latest research from the ... become teenagers, the brains of many preterm children can perform ... study conducted by the University,s Robinson Research Institute ... no brain injury in early life, their cognitive abilities as ... peers. , However, the results of the study, published in ...
(Date:7/28/2014)... approved by the U.S. Food and Drug Administration (FDA) ... certain bacterial pathogens inside human cells, including those that ... findings, published in mBio , the online open-access ... new way of identifying non-antibiotic drugs that could one ... of drugs on the list inhibit the growth of ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... for Research in Vision and Ophthalmology (ARVO) is pleased ... recipients will be acknowledged at the ARVO 2012 Annual ... Proctor Medal: Peter Sterling, PhD, Mildred Weisenfeld Award ... FARVO, Cogan Award: Jeffrey L. Goldberg, MD, PhD, Friedenwald ...
... AMHERST, Mass. A team of kinesiology researchers led ... Amherst recently received a 2.5-year, $975,000 grant through the ... to study how the average 100-lb. equipment load carried ... missions, affects their survivability, likelihood of injury and ability ...
... Md. - The first Maryland municipality to earn a ... is the Town of Berlin on the Eastern Shore. ... by the University of Maryland,s Environmental Finance Center - ... as well as revitalize and improve their long-term quality ...
Cached Biology News:2012 ARVO Award recipients honored at annual meeting 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2Maryland gets its first 'Certified Sustainable' community: Berlin 2
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Biology Products: